Etuvetidigene autotemcel

伊替基奥干赛

Report date: 2026/05/20 15:36:42

Base Information

Drug NameEtuvetidigene autotemcel
Drug Alias NameEtuvetidigene autotemcelWaskyraGSK-2696275OTL-103
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionGene transferenceWiskott-Aldrich syndrome protein stimulants
TargetsWiskott-Aldrich syndrome protein
Therapy Area/IndicationsWiskott-Aldrich Syndrome
Global Approved IndicationsWiskott-Aldrich Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/12/09
Country/TerritoryUnited StatesItalyEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcOspedale San RaffaeleFondazione Telethon
China Registration ClassN/A

Develop Information

Active CompaniesFondazione Telethon ETSGlaxosmithkline PlcOrchard Therapeutics Plc +[5] 
Inactive CompaniesN/A
Active IndicationsWiskott-Aldrich Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank